Download PDF
J Neurol Surg A Cent Eur Neurosurg 2020; 81(03): 253-260
DOI: 10.1055/s-0039-3400497
Review Article
Georg Thieme Verlag KG Stuttgart · New York

Safety of Prophylactic Heparin in the Prevention of Venous Thromboembolism After Spontaneous Intracerebral Hemorrhage: A Meta-analysis

Xi Pan‡   *
1   Departments of Neurology, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, People's Republic of China
,
Jihui Li‡   *
2   Department of Nuclear Medicine, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, People's Republic of China
,
Lan Xu
3   Department of Nursing, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, People's Republic of China
,
Shengming Deng
2   Department of Nuclear Medicine, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, People's Republic of China
,
Zhi Wang
1   Departments of Neurology, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, People's Republic of China
› Author Affiliations
Further Information

Publication History

11 January 2019

03 July 2019

Publication Date:
21 January 2020 (online)

   Permissions and Reprints

Abstract

Objectives Patients with spontaneous intracerebral hemorrhage (sICH) have a nearly fourfold greater risk for venous thromboembolism (VTE) than those with acute ischemic stroke, and VTE after sICH is associated with high risk for in-hospital mortality. The benefit from prophylactic heparin for VTE remains uncertain because its safety is not documented. In this study, we used an updated meta-analysis to evaluate the safety of heparin for the prevention of VTE in patients with sICH.

Methods Electronic databases Medline and Embase from January 1990 to November 2017 and the Cochrane Library were searched using these keywords: intracerebral hemorrhage, stroke, hemorrhagic stroke, subarachnoid hemorrhage, heparin, heparinoids, low-molecular-weight heparin, anticoagulants, prophylactic, low dose, prevention, deep venous thrombosis, pulmonary embolism, venous thrombosis, randomized controlled trial, controlled clinical trial, and outcome. We evaluated the quality of included studies according to the bias risk in the Cochrane Handbook for Systematic Reviews of Interventions v.5.1.0. All statistical analyses were performed with RevMan v.5 software (Cochrane Collaboration, London, United Kingdom). Tests of heterogeneity were conducted with the Mantel-Haenszel method.

Results Nine studies involving 4,055 patients with sICH met the inclusion criteria in this meta-analysis. Of these studies, only one met all specific criteria and had a low probability of bias, whereas eight studies met only some of the criteria and had a moderate probability of bias. In comparison with non-heparin treatments, low-molecular-weight heparin or unfractionated heparin was associated with a nonsignificant increase in any hematoma enlargement, a nonsignificant reduction in extracranial hemorrhage, a nonsignificant increase in mortality, a nonsignificant increase in the number of modified Rankin Scale scores of 3 to 5, and a nonsignificant increase in numbers of Glasgow Outcome Scale scores of 2 to 3.

Conclusion Prophylactic heparin was associated with a nonsignificant increase in any hematoma enlargement and mortality, a nonsignificant reduction in extracranial hemorrhage, and a nonsignificant increase in the incidence of major disability in patients with sICH. It is probably safe to administer heparin to prevent VTE in patients with sICH.

Keywords

heparin - prophylactic - intracerebral hemorrhage - venous thromboembolism

* Xi Pan and Jihui Li contributed equally to this article as first co-authors.


 

  • References

  • 1 Lederle FA, Zylla D, MacDonald R, Wilt TJ. Venous thromboembolism prophylaxis in hospitalized medical patients and those with stroke: a background review for an American College of Physicians Clinical Practice Guideline. Ann Intern Med 2011; 155 (09) 602-615
    CrossrefPubMedGoogle Scholar
  • 2 Gregory PC, Kuhlemeier KV. Prevalence of venous thromboembolism in acute hemorrhagic and thromboembolic stroke. Am J Phys Med Rehabil 2003; 82 (05) 364-369
    PubMedGoogle Scholar
  • 3 Tapson VF, Decousus H, Pini M. , et al; IMPROVE Investigators. Venous thromboembolism prophylaxis in acutely ill hospitalized medical patients: findings from the International Medical Prevention Registry on Venous Thromboembolism. Chest 2007; 132 (03) 936-945
    CrossrefPubMedGoogle Scholar
  • 4 Leizorovicz A, Cohen AT, Turpie AG, Olsson CG, Vaitkus PT, Goldhaber SZ. ; PREVENT Medical Thromboprophylaxis Study Group. Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation 2004; 110 (07) 874-879
    CrossrefPubMedGoogle Scholar
  • 5 Morgenstern LB, Hemphill III JC, Anderson C. , et al; American Heart Association Stroke Council and Council on Cardiovascular Nursing. Guidelines for the management of spontaneous intracerebral hemorrhage: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2010; 41 (09) 2108-2129
    CrossrefPubMedGoogle Scholar
  • 6 Paciaroni M, Agnelli G, Venti M, Alberti A, Acciarresi M, Caso V. Efficacy and safety of anticoagulants in the prevention of venous thromboembolism in patients with acute cerebral hemorrhage: a meta-analysis of controlled studies. J Thromb Haemost 2011; 9 (05) 893-898
    CrossrefPubMedGoogle Scholar
  • 7 Boeer A, Voth E, Henze T, Prange HW. Early heparin therapy in patients with spontaneous intracerebral haemorrhage. J Neurol Neurosurg Psychiatry 1991; 54 (05) 466-467
    CrossrefPubMedGoogle Scholar
  • 8 Hong-chun Y, Wei Y, Li S. The clinical experience for the prevention of thrombosis in deep vein of low limbs in patients with cerebral hemorrhage using low dose of low molecular weight heparin. J Brain Nerv Dis 2015; 23: 209-301
    PubMedGoogle Scholar
  • 9 Orken DN, Kenangil G, Ozkurt H. , et al. Prevention of deep venous thrombosis and pulmonary embolism in patients with acute intracerebral hemorrhage. Neurologist 2009; 15 (06) 329-331
    CrossrefPubMedGoogle Scholar
  • 10 Wasay M, Khan S, Zaki KS. , et al. A non-randomized study of safety and efficacy of heparin for DVT prophylaxis in intracerebral haemorrhage. J Pak Med Assoc 2008; 58 (07) 362-364
    PubMedGoogle Scholar
  • 11 Tetri S, Hakala J, Juvela S. , et al. Safety of low-dose subcutaneous enoxaparin for the prevention of venous thromboembolism after primary intracerebral haemorrhage. Thromb Res 2008; 123 (02) 206-212
    CrossrefPubMedGoogle Scholar
  • 12 Steiner T, Al-Shahi Salman R, Beer R. , et al; European Stroke Organisation. European Stroke Organisation (ESO) guidelines for the management of spontaneous intracerebral hemorrhage. Int J Stroke 2014; 9 (07) 840-855
    CrossrefPubMedGoogle Scholar
  • 13 Hemphill III JC, Greenberg SM, Anderson CS. , et al; American Heart Association Stroke Council; Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology. Guidelines for the Management of Spontaneous Intracerebral Hemorrhage: A Guideline for Healthcare Professionals from the American Heart Association/American Stroke Association. Stroke 2015; 46 (07) 2032-2060
    CrossrefPubMedGoogle Scholar
  • 14 Higgins JP, Green S. Cochrane Handbook for Systematic Reviews of Interventions, v. 5.0.0 (updated February 2008). London, UK: The Cochrane Collaboration; 2008
    Google Scholar
  • 15 O'Carroll CB, Capampangan DJ, Aguilar MI. , et al. What is the effect of low-molecular weight heparin for venous thromboembolism prophylaxis compared with mechanical methods, on the occurrence of hemorrhagic and venous thromboembolic complications in patients with intracerebral hemorrhage? A critically appraised topic. Neurologist 2011; 17 (04) 232-235
    CrossrefPubMedGoogle Scholar
  • 16 Wu TC, Kasam M, Harun N. , et al. Pharmacological deep vein thrombosis prophylaxis does not lead to hematoma expansion in intracerebral hemorrhage with intraventricular extension. Stroke 2011; 42 (03) 705-709
    CrossrefPubMedGoogle Scholar
  • 17 Kiphuth IC, Staykov D, Köhrmann M. , et al. Early administration of low molecular weight heparin after spontaneous intracerebral hemorrhage. A safety analysis. Cerebrovasc Dis 2009; 27 (02) 146-150
    PubMedGoogle Scholar
  • 18 Pan T, Zhang J, Fan GF, Zhang L. Safety of low molecular weight heparin for the prevention of venous thromboembolism after primary intracerebral haemorrhage. Military Med J Southeast China. 2012; 14: 517-519
    PubMedGoogle Scholar
  • 19 Prabhakaran S, Herbers P, Khoury J. , et al. Is prophylactic anticoagulation for deep venous thrombosis common practice after intracerebral hemorrhage?. Stroke 2015; 46 (02) 369-375
    CrossrefPubMedGoogle Scholar
  • 20 Simard JM, Aldrich EF, Schreibman D, James RF, Polifka A, Beaty N. Low-dose intravenous heparin infusion in patients with aneurysmal subarachnoid hemorrhage: a preliminary assessment. J Neurosurg 2013; 119 (06) 1611-1619
    CrossrefPubMedGoogle Scholar
  • 21 Koehler DM, Shipman J, Davidson MA, Guillamondegui O. Is early venous thromboembolism prophylaxis safe in trauma patients with intracranial hemorrhage. J Trauma 2011; 70 (02) 324-329
    CrossrefPubMedGoogle Scholar
  • 22 Phelan HA, Wolf SE, Norwood SH. , et al. A randomized, double-blinded, placebo-controlled pilot trial of anticoagulation in low-risk traumatic brain injury: the Delayed Versus Early Enoxaparin Prophylaxis I (DEEP I) study. J Trauma Acute Care Surg 2012; 73 (06) 1434-1441
    CrossrefPubMedGoogle Scholar
  • 23 Muñoz-Venturelli P, Wang X, Lavados PM. , et al; INTERACT2 Investigators. Prophylactic heparin in acute intracerebral hemorrhage: a propensity score-matched analysis of the INTERACT2 study. Int J Stroke 2016; 11 (05) 549-556
    CrossrefPubMedGoogle Scholar
  • 24 Gu SS, Zhang J, Han L. , et al. Safety of early nadroparin for prevention of deep vein thrombosis in patients with intracerebral hemorrhage. Int J Cerebrovasc Dis 2014; 22: 902-906
    PubMedGoogle Scholar
  • 25 Wurm G, Tomancok B, Nussbaumer K, Adelwöhrer C, Holl K. Reduction of ischemic sequelae following spontaneous subarachnoid hemorrhage: a double-blind, randomized comparison of enoxaparin versus placebo. Clin Neurol Neurosurg 2004; 106 (02) 97-103
    CrossrefPubMedGoogle Scholar
  • 26 Siironen J, Juvela S, Varis J. , et al. No effect of enoxaparin on outcome of aneurysmal subarachnoid hemorrhage: a randomized, double-blind, placebo-controlled clinical trial. J Neurosurg 2003; 99 (06) 953-959
    CrossrefPubMedGoogle Scholar
  • 27 Skaf E, Stein PD, Beemath A, Sanchez J, Bustamante MA, Olson RE. Venous thromboembolism in patients with ischemic and hemorrhagic stroke. Am J Cardiol 2005; 96 (12) 1731-1733
    CrossrefPubMedGoogle Scholar
  • 28 André C, de Freitas GR, Fukujima MM. Prevention of deep venous thrombosis and pulmonary embolism following stroke: a systematic review of published articles. Eur J Neurol 2007; 14 (01) 21-32
    CrossrefPubMedGoogle Scholar
  • 29 Demchuk AM, Dowlatshahi D, Rodriguez-Luna D. , et al; PREDICT/Sunnybrook ICH CTA study group. Prediction of haematoma growth and outcome in patients with intracerebral haemorrhage using the CT-angiography spot sign (PREDICT): a prospective observational study. Lancet Neurol 2012; 11 (04) 307-314
    CrossrefPubMedGoogle Scholar
  • 30 Ovesen C, Christensen AF, Krieger DW, Rosenbaum S, Havsteen I, Christensen H. Time course of early postadmission hematoma expansion in spontaneous intracerebral hemorrhage. Stroke 2014; 45 (04) 994-999
    CrossrefPubMedGoogle Scholar
  • 31 Jauch EC, Lindsell CJ, Adeoye O. , et al. Lack of evidence for an association between hemodynamic variables and hematoma growth in spontaneous intracerebral hemorrhage. Stroke 2006; 37 (08) 2061-2065
    CrossrefPubMedGoogle Scholar
  • 32 Riha GM, Van PY, Differding JA, Schreiber MA. ; Oregon Health & Science University Trauma Research Group. Incidence of deep vein thrombosis is increased with 30 mg twice daily dosing of enoxaparin compared with 40 mg daily. Am J Surg 2012; 203 (05) 598-602
    CrossrefPubMedGoogle Scholar
  • 33 Malinoski D, Jafari F, Ewing T. , et al. Standard prophylactic enoxaparin dosing leads to inadequate anti-Xa levels and increased deep venous thrombosis rates in critically ill trauma and surgical patients. J Trauma 2010; 68 (04) 874-880
    CrossrefPubMedGoogle Scholar
  • 34 Keskin I, Gunal MY, Ayturk N, Kilic U, Ozansoy M, Kilic E. Dose-dependent neuroprotective effect of enoxaparin on cold-induced traumatic brain injury. Neural Regen Res 2017; 12 (05) 761-764
    CrossrefPubMedGoogle Scholar
  • 35 Yi X, Chi W, Wang C, Zhang B, Lin J. Low-molecular-weight heparin or dual antiplatelet therapy is more effective than aspirin alone in preventing early neurological deterioration and improving the 6-month outcome in ischemic stroke patients. J Clin Neurol 2015; 11 (01) 57-65
    CrossrefPubMedGoogle Scholar